The global specialty generics market size reached US$ 67.4 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 125.4 Billion by 2028, exhibiting a growth rate (CAGR) of 10.8% during 2023-2028.
Specialty generics are generic versions of specialty drugs, once they get off-patent. These drugs are used to treat chronic or complex health conditions including cancer, autoimmune diseases, epilepsy, HIV, Hepatitis, multiple sclerosis, rheumatoid arthritis, etc. Speciality generics are cost-effective as compared to their branded versions as they don't require costly development and marketing costs.
Compared to traditional generics, the speciality generics market is more concentrated with fewer players due to their complex manufacturing requirements, higher capital costs and relatively lower volumes as a result of smaller patient population. This results in lower price reduction compared to the branded drug and consequently higher margins compared to traditional generics. Speciality generics require special handling, administration, monitoring and generally need prior authorization to order them. The global speciality generics market is currently being driven by several factors such as rising ageing population, patent expiration of a number of branded specialty drugs, increasing prevalence of various life-threatening diseases such as cancer, multiple sclerosis, HIV, etc., cost containment measures from healthcare providers, growth from emerging markets, etc.
The publisher's latest report provides a deep insight into the global specialty generics market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the specialty generics market in any manner.
2. What are the key factors driving the global specialty generics market?
3. What has been the impact of COVID-19 on the global specialty generics market?
4. What is the breakup of the global specialty generics market based on the route of administration?
5. What is the breakup of the global specialty generics market based on the indication?
6. What is the breakup of the global specialty generics market based on the distribution channel?
7. What are the key regions in the global specialty generics market?
8. Who are the key players/companies in the global specialty generics market?
Specialty generics are generic versions of specialty drugs, once they get off-patent. These drugs are used to treat chronic or complex health conditions including cancer, autoimmune diseases, epilepsy, HIV, Hepatitis, multiple sclerosis, rheumatoid arthritis, etc. Speciality generics are cost-effective as compared to their branded versions as they don't require costly development and marketing costs.
Compared to traditional generics, the speciality generics market is more concentrated with fewer players due to their complex manufacturing requirements, higher capital costs and relatively lower volumes as a result of smaller patient population. This results in lower price reduction compared to the branded drug and consequently higher margins compared to traditional generics. Speciality generics require special handling, administration, monitoring and generally need prior authorization to order them. The global speciality generics market is currently being driven by several factors such as rising ageing population, patent expiration of a number of branded specialty drugs, increasing prevalence of various life-threatening diseases such as cancer, multiple sclerosis, HIV, etc., cost containment measures from healthcare providers, growth from emerging markets, etc.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global specialty generics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on route of administration, indication and distribution channel.Breakup by Region:
North America
- United States
- Canada
Europe
- Italy
- Germany
- Spain
- United Kingdom
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
Latin America
- Brazil
- Mexico
- Middle East and Africa
Breakup by Route of Administration:
- Injectables
- Oral
- Others
Breakup by Indication:
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Others
Breakup by Distribution channel:
- Retail Pharmacies
- Specialty Pharmacies
- Hospital Pharmacies
Competitive Landscape:
The global specialty generics market consists of numerous manufacturers. Some of the leading players operating in the market are Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp., Endo International plc.The publisher's latest report provides a deep insight into the global specialty generics market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the specialty generics market in any manner.
Key Questions Answered in This Report
1. What is the size of the global specialty generics market?2. What are the key factors driving the global specialty generics market?
3. What has been the impact of COVID-19 on the global specialty generics market?
4. What is the breakup of the global specialty generics market based on the route of administration?
5. What is the breakup of the global specialty generics market based on the indication?
6. What is the breakup of the global specialty generics market based on the distribution channel?
7. What are the key regions in the global specialty generics market?
8. Who are the key players/companies in the global specialty generics market?
Table of Contents
1 Preface3 Executive Summary4 Global Specialty Generics Market: Introduction5 Why are Specialty Generics So Lucrative?10.1.3.1.1 Market Trends10.1.3.2.1 Market Trends10.2.3.1.1 Market Trends10.2.3.2.1 Market Trends10.2.3.3.1 Market Trends10.2.3.4.1 Market Trends10.2.3.5.1 Market Trends10.3.3.1.1 Market Trends10.3.3.2.1 Market Trends10.3.3.3.1 Market Trends10.3.3.4.1 Market Trends10.4.3.1.1 Market Trends10.4.3.2.1 Market Trends
2 Scope and Methodology
6 Global Specialty Generics Market
7 Market Breakup by Route of Administration
8 Market Breakup by Indication
9 Market Breakup by Distribution Channel
10 Market Breakup by Region
10.1.3.1.2 Market Forecast
10.1.3.2.2 Market Forecast
10.2.3.1.2 Market Forecast
10.2.3.2.2 Market Forecast
10.2.3.3.2 Market Forecast
10.2.3.4.2 Market Forecast
10.2.3.5.2 Market Forecast
10.3.3.1.2 Market Forecast
10.3.3.2.2 Market Forecast
10.3.3.3.2 Market Forecast
10.3.3.4.2 Market Forecast
10.4.3.1.2 Market Forecast
10.4.3.2.2 Market Forecast
11 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Teva Pharmaceuticals Industries
- Akorn Inc.
- Mylan N.V.
- Mallinckrodt
- Sandoz International GmbH
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals
- Apotex Corp.
- Endo International plc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 146 |
| Published | June 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 67.4 Billion |
| Forecasted Market Value ( USD | $ 125.4 Billion |
| Compound Annual Growth Rate | 10.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
